This award recognizes Dr. Nkrumah-Elie’s dedication to advancing scientific excellence for ChromaDex’s leading external research program and mentorship in the dietary supplement industry

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex’s Global Director of External Research, as the winner of the inaugural Trailblazing Woman Award.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015810330/en/

Yasmeen Nkrumah-Elie, Ph.D accepts the Trailblazing Woman Award on stage during CRN’s CONVERGENCE Conference (Photo: Business Wire)

“I am deeply honored to receive the Trailblazing Woman Award,” said Dr. Nkrumah-Elie, “and I am moved by the collective force of inspiring women leading within our dietary supplement industry who continue to push the boundaries of what’s possible—as my fellow finalists demonstrate. I am grateful for the opportunity to be a part of an industry dedicated to advancing wellness and improving global health.”

The Trailblazing Woman Award honors women who have made remarkable contributions to the dietary supplement and functional food industry through leadership, innovation, and mentorship. Dr. Nkrumah-Elie was selected for her extraordinary commitment to advancing science, promoting diversity, and mentoring the next generation of female leaders.

In addition to her leadership role at ChromaDex, Dr. Nkrumah-Elie is a member of CRN’s Senior Scientific Advisory Council and actively contributes to several industry organizations, including Women In Nutraceuticals (WIN) and the American Society for Nutrition, where she advocates for diversity, equity, and inclusion. She is a frequent speaker at industry conferences, where she shares her knowledge and helps bridge the gap between science and broader audiences.

Andrew Shao, PhD., Senior Vice President, Global Scientific and Regulatory Affairs, ChromaDex, commented: “Dr. Nkrumah-Elie has led the evolution of the ChromaDex External Research Program (CERP) to become an award-winning and industry-leading research program. Under her leadership, CERP has amassed nearly 300 research collaborations with institutions around the world, over 30 published clinical trials and several intellectual property opportunities. Dr. Nkrumah-Elie and her dedicated team have elevated CERP to become the gold standard for industry-academia collaboration.”

“We’re thrilled to celebrate Dr. Nkrumah-Elie’s remarkable achievements and the lasting impact she’s made on our industry,” said Pelin Thorogood, Co-Founder and Executive Chairwoman of Radicle Science. “A brilliant researcher, Dr. Nkrumah-Elie’s influence extends far beyond her scientific contributions—she’s a mentor, a connector, and a fierce advocate for women in science. Her passion for creating opportunities and uniting people in meaningful ways is why she’s such a worthy recipient of our inaugural Trailblazing Woman Award.”

“We appreciate Dr. Nkrumah-Elie’s engagement and leadership in the CRN member community,” said Andrea Wong, Ph.D., CRN Senior Vice President, Scientific and Regulatory Affairs. “Her depth of knowledge, combined with her dedication to advancing scientific excellence and mentoring future generations, has made a significant impact.”

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

ChromaDex Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com

ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more ChromaDex Charts.
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more ChromaDex Charts.